One year follow-up of hormone replacement therapy with percutaneous estradiol and low-dose vaginal natural progesterone in women with mild to moderate hypertension

Experimental and Clinical Endocrinology and Diabetes

Volumn 111, Issue 5, 2003, Pages 267-273

  Spritzer, Poli Mara ^a   Vitola, D ^b   Vilodre, L C ^a   Wender, M C O ^c   Reis, F M ^a   Ruschel, S ^c   Castro, I ^b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b Cardiology Institut   (Brazil)

^c Univ Federal do Rio Grande do Sul ^*

Author keywords

Cutaneous administration; HRT; Lipoproteins; Menopause; Progesterone

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANGIOTENSIN; ANTITHROMBIN III; CHOLESTEROL; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RENIN; SEX HORMONE; TRIACYLGLYCEROL;

ADULT; ALDOSTERONE BLOOD LEVEL; ANALYSIS OF VARIANCE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR PARAMETERS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; ESTROGEN THERAPY; EVALUATION; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE WALL; HEART RATE; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; LIVER METABOLISM; LOW DRUG DOSE; MENOPAUSAL SYNDROME; OUTCOMES RESEARCH; PLASMA RENIN ACTIVITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK BENEFIT ANALYSIS; SYMPTOM;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRAVAGINAL; ALDOSTERONE; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HEART RATE; HUMANS; HYPERTENSION; POSTURE; PROGESTERONE; RENIN; TIME FACTORS; VAGINA;

EID: 0042035629     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-41753     Document Type: Article

References (39)

1. Affinito P, Palomba S, Bonifacio M, Fontana D, Izzo R, Trimarco B, Nappi C. Effects of hormonal replacement therapy in postmenopausal hypertensive patients. Maturitas 2001; 40: 75-83
2. American College of Obstetricians and Gynecologists. Hormone Replacement Therapy. ACOG Educational Bulletin. Washington DC, 1998
3. Barrett-Connor E, Slone S, Greendale G, Kritz-Silverstein D, Espeland M,Johnson SR, Waclawiw M, Fineberg SE. The Postmenopausal Estrogen/Progestin Interventions study: primary outcomes in adherent women. Maturitas 1997; 24: 261-274
4. Barrett-Connor E, Wingard D, Criqui MH. Post-menopausal estrogen use and heart disease risk factors in the 1980s. JAMA 1989; 261: 2095-2100
5. Bonduki CE, Lourenço DM, Baracat E, Haidar M, Noguti MA, da Motta EL, Lima GR. Effect of estrogen-progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women. Acta Obstet Gynecol Scand 1998; 77: 330-333
6. Cheitlin MD, Alpert JS, Armstrong WF, Aurigemma GP, Better GA, Bierman FZ, Davidson TW, Davis JL, Douglas PS, Gillam LD. ACC/AHA guidelines for the clinical application of echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. Circulation 1997; 95: 1686-1744
7. Christ M, Seyffart K, Tillmann HC, Wehling M. Hormone replacement in postmenopausal women: impact of progestogens on autonomic tone and blood pressure regulation. Menopause 2002; 9: 127-136
8. Clinical Synthesis Panel on HRT. Hormone replacement therapy. Lancet 1999; 354: 152-155
9. Col NF, Eckman MH, Karas RH, Pauker SG, Goldberg RJ, Ross EM, Orr RK, Wong JB. Patient-specific decisions about hormone replacement therapy in post-menopausal women. JAMA 1997; 277: 1140-1147
10. De Lignieres B, Basdevant A, Thomas G, Thalabard J-C, Mercier-Bodard C, Conard J, Guyene TT, Mairon N, Corvol P, Guy-Grand B, Mauvais-Jarvis P, Sitruk-Ware R. Biological effects of estradiol-17β in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 1986; 62: 536-541
11. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338: 736-746
12. Harvey PJ, Molloy D, Upton J, Wing LM. Dose response effect of conjugated equine oestrogen on blood pressure in postmenopausal women with hypertension. Blood Press 2000; 9: 275-282
13. Hoibraaten E, Os 1, Seljeflot 1, Andersen TO, Hofstad A, Sandset PM. The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: results from the estrogen in women with atherosclerosis study. Thromb Res 2000; 98: 19-27
14. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-613
15. Joint National Committee. The 1988 report of the Joint National Committee on detection, evaluation and treatment of high blood pressure. Arch Intern Med 1988; 148: 1023-1038
16. Khoo SK, Coglan MJ, Wright GR, DeVoss KN, Battistutta D. Hormone therapy in women in the menopause transition. Randomised, double-blind, placebo-controlled trial of effects on body weight, blood pressure, lipoprotein levels, antithrombin III activity, and the endometrium. Med J Aust 1998; 168: 216-220
17. Kupperman HS, Blatt MH, Weisbader H, Filler W. Comparative clinical evaluation of estrogenic preparation by the menopausal and amenorrhea indices. J Clin Endocrinol Metab 1953; 6: 688-703.
18. Lip GYH, Beevers M, Churchill D, Beevers DG. Hormone replacement therapy and blood pressure in hypertensive women. J Hum Hypertens 1994; 8: 491-494
19. Lobo RA. Cardiovascular implications of estrogen replacement therapy. Obstet Gynecol 1990; 75 (Suppl 4): S18-S25
20. Lobo RA. Different types of estrogens and progestins. Obstet Gyn Clin N Am 1987; 14: 143-167
21. Manhem K, Ahlm H, Milsom 1, Sevensson A. Transdermal oestrogen reduces daytime blood pressure in hypertensive women. J Hum Hypertens 1998; 12: 323-327
22. Mashchak CA, Lobo RA. Estrogen replacement therapy and hypertension. J Reprod Med 1985; 30 (Suppl 10): 805-810
23. Maturana MA, Spritzer PM. Association between hyperinsulinemia and endogenous androgen levels in peri and postmenopausal women. Metabolism 2002; 51: 238-243
24. Mercuro G, Zoncu S, Piano D, Pilia 1, Lao A, Metis GB, Cherchi A. Estradiol-17beta reduces blood pressure and restores the normal amplitude of the circadian blood pressure rhythm in postmenopausal hypertension. Am J Hypertens 1998; 11: 909-913
25. Modena MG, Molinari R, Muia N Jr., Castelli A, Pala F, Rossi R. Doubleblind randomized placebo-controlled study of transdermal estrogen replacement therapy on hypertensive postmenopausal women. Am J Hypertens 1999; 12: 1000-1008
26. Mukherjee M, DeLorenzo F, Kadziola Z, Rutlin A, Ranlall N, Sembhi K, Dawson G, Kakkar VV. Correlation of circulating 17 beta-oestradiol with haemostatic factors in healthy postmenopausal women. Haemostasis 1999; 29: 336-342
27. Schunkert H, Danser AH, Hense HW, Derkx. FH, Kurzinger S. Riegger GA. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 1997: 95: 39-45
28. Seely EW, Walsh BW, Gerhard MD, Williams GH. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension 1999; 33: 1190-1194
29. Shionoirib H, Eggena P, Barrett JD, Thananopavarn C, Golub MS, Eggena Z, Nakamura R,Judd HL, Sambhi MP. An increase in high-molecular weight renin substrate associated with estrogenic hypertension. Biochem Med 1983: 29: 14-22
30. Skafar DF, Xu R, Morales J, Ram J, Sowers JR. Female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab 1997; 82: 3913-3918
31. Spritzer PM, Vilodre LC, Magalhaes JA, Wender MCO, Reis FM, Ruschel S. Effects of percutaneous 17β-estradiol and vaginal micronized progesterone replacement therapy on endometrial thickness and pattern of vaginal [abstract]. Gynecol Endocrinol 1998a; 12 (Suppl 2): FC72
32. Spritzer PM, Vitola D, Wender MCO, Ruschel S, Reis FM, Vilodre LC. Metabolic effects of percutaneous 17β-estradiol and vaginal micronized progesterone in hyperlipidemic postmenopausal women [free communication]. 6th Congress of the International Society of Gynecological Endocrinology, March 1998, Crans-Montana, Switzerland. Gynecol Endocrinol 1998 b; 12 (Suppl 2): FC75
33. Szekacs B, Vajo Z, Acs N, Hada P, Csuzi L, Bezeredi J, Magyar Z, Brinton EA. Hormone replacement therapy reduces mean 24-hour blood pressure and its variability in postmenopausal women with treated hypertension. Menopause 2000; 7: 31-35
34. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995: 273: 199-208
35. van Baal WM, Emeis JJ, van der Mooren MJ, Kessel H, Kenemans P, Stehouwer CD. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study. Thromb Haemost 2000; 83: 29-34
36. Vongpatanasin W, Tuncel M, Mansour Y, Arbique D, Victor RG. Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women. Circulation 2001; 103: 2903-2908
37. Weir RJ, Briggs E, Mack A, Naismith L, Taylor L, Wilson E. Blood pressure in women taking oral contraceptives. Br Med J 1974; 1: 533-535
38. Wolf BM, Finkle WD. Effects of combined estrogen and progestin administration on plasma lipoprotein metabolism in post-menopausal women. J Clin Invest 1989; 83: 40-45
39. Zar JH. Biostatistical Analysis. 3rd ed. Upper Saddle River: Prentice Hall, 1996: 265-266